Table 2.
Study | All grades
|
Grades 3/4
|
||||||
---|---|---|---|---|---|---|---|---|
Events | Incidence (%) | Incidence in RECORD-1 (updated)29 (%) | Incidence in RECORD-128 (%) | Events | Incidence (%) | Incidence in RECORD-1 (updated)29 (%) | Incidence in RECORD-128 (%) | |
Guo et al27 | Anemia | 64 | 92 | 91 | Anemia | 20 | 13 | <10 |
Hypertriglyceridemia | 55 | 73 | 71 | Hyperglycemia | 13 | <16 | 12 | |
Mouth ulceration | 53 | 44a | 40a | Increased GGT | 11 | – | – | |
Hyperglycemia | 52 | 57 | 50 | Hyponatremia | 8 | – | – | |
Hypercholesterolemia | 50 | 77 | 76 | Dyspnea | 8 | 24 | 7 | |
Pyrexia | 41 | 20 | – | Hypertriglyceridemia | 6 | <1 | <1 | |
Increased lactate dehydrogenase | 38 | – | – | Lymphopenia | 6 | 18 | 0 | |
Fatigue | 31 | 31 | 20 | Noninfectious pneumonitis | 6 | 4 | 3 | |
Increased GGT | 31 | – | – | |||||
Rash | 31 | 29 | 25 | |||||
Noninfectious pneumonitisb | 31 | 14b | 8b | |||||
Huang et al30 | Anemia | 70.8 | 92 | 91 | Anemia | 25.0 | 13 | <10 |
Hypercholesterolemia | 66.7 | 77 | 76 | Hyperglycemia | 16.7 | <16 | 12 | |
Hypertriglyceridemia | 65.0 | 73 | 71 | Mucositis | 8.3 | 1 | 1 | |
Mucositis | 54.2 | 19 | 14 | Pneumonitis | 8.3 | 4 | 3 | |
Hyperglycemia | 50.0 | 57 | 50 | Raised ALP | 8.3 | – | <1 | |
Rash | 45.8 | 29 | 25 | |||||
Raised ALP | 25.0 | – | 37 | |||||
Thrombocytopenia | 20.8 | – | 20 | |||||
Raised AST/ALT | 20.5 | 25/21c | 21/18c | |||||
Pneumonitis | 16.4 | 14 | 8 |
Notes:
References analyzed stomatitis which includes aphthous stomatitis, mouth ulceration, and stomatitis
noninfectious pneumonitis in the study by Guo et al includes interstitial lung disease, pneumonitis, and pulmonary fibrosis. References analyzed pneumonitis which includes interstitial lung disease, lung infiltration, pneumonitis, pulmonary alveolar hemorrhage, alveolitis, and pulmonary toxicity.
Incidence of AST and ALT was listed according to the reference, respectively.
Abbreviations: GGT, gamma-glutamyl transferase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; RECORD-1, renal cell cancer treatment with oral RAD001 given daily.